Impact of Phytotherapy on Utility Scores for 5 Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms Health States

Journal of Urology

Volumn 179, Issue 1, 2008, Pages 220-225

  Dedhia, Raj C ^a   Calhoun, Elizabeth ^b   McVary, Kevin T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

health; phytotherapy; prostate; prostatic hyperplasia; urinary tract

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PLANT MEDICINAL PRODUCT; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HEALTH STATUS; HUMAN; LOWER URINARY TRACT SYMPTOM; MALE; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TWO TAILED TEST; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION;

AGED; HEALTH STATUS; HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PLANT PREPARATIONS; PROSTATIC HYPERPLASIA; PROSTATISM; PYGEUM; QUESTIONNAIRES;

EID: 36749090705     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.08.152     Document Type: Article

References (18)

1. Harbitz T.B., and Haugen O.A. Histology of the prostate in elderly men. A study in an autopsy series. Acta Pathol Microbiol Scand 80 (1972) 756 [A]
2. Randall A. Surgical pathology of prostatic obstructions (1931), Williams & Wilkins Co, Baltimore xiii
3. Disantostefano R.L., Biddle A.K., and Lavelle J.P. The long-term cost effectiveness of treatments for benign prostatic hyperplasia. Pharmacoeconomics 24 (2006) 171
4. Jepsen J.V., and Bruskewitz R.C. Comprehensive patient evaluation for benign prostatic hyperplasia. Urology 51 (1998) 13
5. Saigal C.S., and Joyce G. Economic costs of benign prostatic hyperplasia in the private sector. J Urol 173 (2005) 1309
6. Rosen R., Altwein J., Boyle P., Kirby R.S., Lukacs B., Meuleman E., et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44 (2003) 637
7. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole G.L., Dixon C.M., Kusek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387
8. Schulz M.W., Chen J., Woo H.H., Keech M., Watson M.E., and Davey P.J. A comparison of techniques for eliciting patient preferences in patients with benign prostatic hyperplasia. J Urol 168 (2002) 155
9. Buckingham J.K., Birdsall J., and Douglas J.G. Comparing three versions of the time tradeoff: time for a change?. Med Decis Making 16 (1996) 335
10. Marwick C. Growing use of medicinal botanicals forces assessment by drug regulators. JAMA 273 (1995) 607
11. Bales G.T., Christiano A.P., Kirsh E.J., and Gerber G.S. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urology 54 (1999) 86
12. Lowe F.C., and Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology 53 (1999) 671
13. Ishani A., MacDonald R., Nelson D., Rutks I., and Wilt T.J. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med 109 (2000) 654
14. Brevoort P. The U.S. botanical market-an overview. HerbalGram 36 (1996) 49
15. Muller J., and Clauson K.A. Pharmaceutical consideration of common herbal medicine. Am J Manag Care 3 (1997) 1753
16. Kok E.T., McDonnell J., Stolk E.A., Stoevelaar H.J., Busschbach J.J.a., and Triumph Research Group. The valuation of the International Prostate Symptom Score (IPSS) for use in economic evaluations. Eur Urol 42 (2002) 491
17. Gold M., Patrick D.L., Torrace G.W., Fryback D.G., Hadorn D.C., Kamlet M.S., et al. Identifying and valuing outcomes. In: Gold M., Siegle J., Russel L., and Weintsein M. (Eds). Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, New York 82-134
18. Astin J.A. Why patients use alternative medicine: results of a national study. JAMA 279 (1998) 1548